Intellia Therapeutics (NTLA) Misses Q4 EPS by 2c
Tweet
Share
E-mail
Get Alerts NTLA Hot Sheet
Join SI Premium – FREE
Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($1.46), $0.02 worse than the analyst estimate of ($1.44).
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
